Cambridge Investment Research Advisors
IBRX icon

Cambridge Investment Research Advisors’s ImmunityBio IBRX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.18M Sell
284,704
-5,873
-2% -$40.2K 0.01% 1523
2025
Q4 		$575K Buy
290,577
+220,287
+313% +$499K ﹤0.01% 2585
2025
Q3 		$173K Buy
70,290
+49,340
+236% +$127K ﹤0.01% 3522
2025
Q2 		$55K Buy
20,950
+3,000
+17% +$8.07K ﹤0.01% 3532
2025
Q1 		$54K Buy
+17,950
New +$54.4K ﹤0.01% 3400
2024
Q4 		– Sell
-14,519
Closed -$54K – 3535
2024
Q3 		$54K Buy
14,519
+700
+5% +$3.24K ﹤0.01% 3325
2024
Q2 		$87K Sell
13,819
-631
-4% -$4.16K ﹤0.01% 3171
2024
Q1 		$78K Sell
14,450
-500
-3% -$2.26K ﹤0.01% 3175
2023
Q4 		$75K Hold
14,950
– – ﹤0.01% 3067
2023
Q3 		$25K Hold
14,950
– – ﹤0.01% 3074
2023
Q2 		$42K Buy
14,950
+1,000
+7% +$2.83K ﹤0.01% 3091
2023
Q1 		$25K Buy
13,950
+2,000
+17% +$6.22K ﹤0.01% 3091
2022
Q4 		$61K Buy
+11,950
New +$65.6K ﹤0.01% 2960
2021
Q3 		– Sell
-28,568
Closed -$408K – 3144
2021
Q2 		$408K Buy
+28,568
New +$472K ﹤0.01% 2219

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cambridge Investment Research Advisors's IBRX Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its ImmunityBio (IBRX) stake by 2% in Q1 2026, selling an estimated $40.2K and leaving 284,704 shares worth $2.18M. The position accounts for 0.01% of the portfolio, ranked #1523.

Cambridge Investment Research Advisors first reported a position in IBRX in Q2 2021 and has held it in 14 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Cambridge Investment Research Advisors held 284,704 shares of ImmunityBio worth $2.18M as of Q1 2026.
  • Cambridge Investment Research Advisors sold 5,873 ImmunityBio shares in Q1 2026, an estimated $40.2K.
  • ImmunityBio made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #1523 holding.
  • Cambridge Investment Research Advisors first reported a position in ImmunityBio in Q2 2021 and has held it in 14 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.